Dogwood Therapeutics (DWTX) Net Cash Flow (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Net Cash Flow of $6.7 million for Q1 2026, up 149.24% year-over-year from $2.7 million in Q1 2025, and up 285.99% quarter-over-quarter from -$3.6 million in Q4 2025.
Dogwood Therapeutics (DWTX) Net Cash Flow (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Net Cash Flow for 7 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 149.24% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at -$4.3 million (down 142.82% YoY), while the FY2025 annual figure was -$8.3 million, down 171.38% from the prior year.
- Net Cash Flow grew to $6.7 million in Q1 2026 per DWTX's latest filing, from -$3.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $9.2 million in Q4 2024 and bottomed at -$4.1 million in Q2 2025.
- Historically, Net Cash Flow has averaged -$681925.1 across 5 years, with a median of -$1.5 million in 2023.
- Annual changes were most pronounced in 2024 — Net Cash Flow surged 725.58% — and 2025, when it sank 410.78%.
- Dogwood Therapeutics' Net Cash Flow stood at -$2.8 million in 2022, then surged by 46.72% to -$1.5 million in 2023, then soared by 725.58% to $9.2 million in 2024, then slumped by 139.22% to -$3.6 million in 2025, then soared by 285.99% to $6.7 million in 2026.
- Business Quant data shows DWTX's Net Cash Flow at $6.7 million in Q1 2026, -$3.6 million in Q4 2025, and -$3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Dogwood Therapeutics | 74.06 Mn | 74.06 Mn | - | -3.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.70 Mn |
| Mar 31, 2026 | 6.70 Mn |
| Dec 31, 2025 | -3.60 Mn |
| Dec 31, 2025 | -3.60 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Jun 30, 2025 | -4.15 Mn |
| Jun 30, 2025 | -4.15 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Dec 31, 2024 | 9.19 Mn |
| Dec 31, 2024 | 9.19 Mn |
| Sep 30, 2024 | -980,364.00 |
| Sep 30, 2024 | -980,364.00 |
| Jun 30, 2024 | -811,746.00 |
| Jun 30, 2024 | -811,746.00 |
| Mar 31, 2024 | -937,414.00 |
| Mar 31, 2024 | -937,414.00 |
| Dec 31, 2023 | -1.47 Mn |
| Dec 31, 2023 | -1.47 Mn |